|
 |
 |
| Management of Dyspepsia and Heartburn |
On September 30, 2004, Vioxx (rofecoxib) was withdrawn from the U.S. and worldwide market due to safety concerns of an increased risk of cardiovascular events. See the U.S. Food and Drug Administration (FDA) Web site for more information. Subsequently, on December 23, 2004, the FDA issued a public health advisory concerning the use of non-steroidal anti-inflammatory drug products (NSAIDs) including the COX-2 selective agents Celebrex (celecoxib), Bextra (valdecoxib) and a non-selective NSAID, naproxen (sold as Aleve, Naprosyn and other trade name and generic products). See the FDA web site for more information.
Alternative analgesics/anti-inflammatories should be considered first. Co-therapy may be required to prevent adverse effects (eg, dyspepsia, gastrointestinal bleeding) in selected at-risk patients, The COX-2 drugs listed above should only be used after careful consideration of the risks, benefits and costs related to each specific patient where this choice is made. |
|
|
|
Title |
Format |
Size |
|
|
 |
Management of Dyspepsia and Heartburn – Summary |
pdf |
623 k |
|
|
|
|
|
| « Back |
|
|
